Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Weitzman

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
JAMA Oncology|September 27, 2019
Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical TrialAmylou C Dueck, Howard I Scher, Antonia V Bennett, et al.
Chemical Research in Toxicology|March 13, 2023
Untargeted Metabolomics to Characterize the Urinary Chemical Landscape of E-Cigarette UsersYun-Chung Hsiao, Richard S Matulewicz, Scott E Sherman, et al.
Journal of Wildlife Diseases|October 28, 2016
COMPARISON OF CURRENT METHODS FOR THE DETECTION OF CHRONIC MYCOPLASMAL URTD IN WILD POPULATIONS OF THE MOJAVE DESERT TORTOISE (GOPHERUS AGASSIZII)Franziska C Sandmeier, Chava L Weitzman, K Nichole Maloney, et al.
The Journal of Urology|February 25, 2000
Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancerA L Weitzman, G Shelton, N Zuech, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
European Urology|December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain EndpointEthan M Basch, Mark Scholz, Johann S de Bono, et al.
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
JAMA Oncology|September 27, 2019
Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical TrialAmylou C Dueck, Howard I Scher, Antonia V Bennett, et al.
Chemical Research in Toxicology|March 13, 2023
Untargeted Metabolomics to Characterize the Urinary Chemical Landscape of E-Cigarette UsersYun-Chung Hsiao, Richard S Matulewicz, Scott E Sherman, et al.
Journal of Wildlife Diseases|October 28, 2016
COMPARISON OF CURRENT METHODS FOR THE DETECTION OF CHRONIC MYCOPLASMAL URTD IN WILD POPULATIONS OF THE MOJAVE DESERT TORTOISE (GOPHERUS AGASSIZII)Franziska C Sandmeier, Chava L Weitzman, K Nichole Maloney, et al.
The Journal of Urology|February 25, 2000
Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancerA L Weitzman, G Shelton, N Zuech, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
European Urology|December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain EndpointEthan M Basch, Mark Scholz, Johann S de Bono, et al.
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Pageof 6